But the bar is just higher right now [] and the totality of the data set around 786 did not meet the bar that we have for medicines that we would advance into Phase II clinical investigation for obesity. Peter Griffith, Amgens chief financial officer, confirmed Amgens interest to obesity medications: In terms of allocating capital to obesity, we view it as a platform
Manufactured to high purity standards and batch tested using analytical methods
GLP-1 benefits reach well beyond weight management, with these medications contributing to the first decline of U.S
If HbA1c doesn't improve after 3 months on medication, dosing or approach may need adjustment
We discussed the IGF-1 and cancer-surveillance conversation in the post on tesamorelin for visceral fat, and the same principles apply here
It is able to work in a similar way to our naturally occurring GLP-1 in the body and therefore has very similar effects including: Increase release of insulin when blood sugar is elevated